Sentiment Summary
Recent Events
The Annual General Meeting (AGM) for shareholders is scheduled for June 16, 2026. Low importance is estimated as standard shareholder meetings typically result in a price impact of at least 1%, so this event is scheduled.
Analysts forecast EPS of $1.58 for the Q4 and full-year fiscal 2026 earnings release and conference call on 2026-06-03. High importance is estimated based on potential price impact ≥10% from the results, scheduled
The 2026 Annual Meeting of Stockholders is scheduled for June 3, 2026, to vote on director elections and plan amendments; routine governance events usually have <5% price impact expected.
Ex-dividend date for final dividend of HKD 0.539 and special dividend of HKD 0.6714 per share on 2026-06-01; low impact estimated as a routine distribution, scheduled.
Annual General Meeting on 2026-05-28; low impact estimated as a routine administrative meeting, scheduled.
A planned board leadership transition on 2026-05-20, where current director Donald J. Spence is intended to be appointed as the new independent Chair, succeeding Pamela G. Bailey, with low market impact expected as this is a planned succession scheduled.
Publication of the full-year results for the fiscal year 2025/26 (ending March 31, 2026) is scheduled for May 18, 2026. High importance is estimated as annual earnings reports typically trigger price movements of 10% or more, so this event is scheduled.
CeriBell to report First Quarter 2026 financial results on May 11, 2026, with an estimated price impact of ≥5%, scheduled.
Globus Medical is scheduled to announce its Q1 2026 financial results on May 7, 2026; earnings releases are major catalysts typically causing >5% price volatility expected.
Earnings release for Q2 2025/26. I estimate a medium importance as earnings reports can significantly impact stock prices based on results and outlook; scheduled.
First-quarter 2026 earnings results and conference call are scheduled for 2026-05-06. This routine announcement is estimated to result in a price impact of ≥1% scheduled.
Inspire Medical Systems is scheduled to report its Q1 2026 financial results on May 4, 2026. Analysts are forecasting a year-over-year decline in revenue and a loss per share of approximately ($0.34) to ($0.36) scheduled.
First quarter 2026 financial results and conference call on 2026-04-30, with a significant market reaction expected due to anticipated updates on full-year guidance and product headwinds scheduled.
Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026, with a conference call to follow. High importance is estimated due to the potential for significant price volatility exceeding 10% based on historical earnings trends, scheduled.
Alphabet is scheduled to report its Q1 2026 financial results on April 29, 2026. Analysts forecast EPS of approximately $2.63 on revenues of $106.9 billion; high importance due to expected market volatility scheduled.
Announced on April 29, 2026, that its subsidiary Henlius' Pertuzumab biosimilar (POHERDY®) received marketing authorization from the European Commission for treating HER2-positive breast cancer.
Released Q1 2026 results on April 28, 2026, with revenue up 15.17% YoY but net profit attributable to shareholders down 70.36% YoY to CNY 49.04 million.
Announced Q1 2026 results on 2026-04-28, reporting a net profit of CNY 328 million, a significant turnaround from a net loss of CNY 254 million in Q1 2025. Revenue grew 24.76% year-over-year to CNY 656 million. This turnaround is estimated to have a ≥10% price impact, scheduled.
Announced and open-sourced the SenseNova U1 series, a new native unified model for language and vision, on April 28, 2026. Market reaction is estimated to be positive with a medium impact as this represents a significant technological advancement in generative AI.
Announced Q1 2026 results on April 28, 2026, with revenue of RMB 10.073 billion (+6.93% YoY) and net profit attributable to shareholders of RMB 871 million (+13.87% YoY).
Released Q1 2026 results on April 28, 2026, with revenue up 15.5% YoY to RMB 3.58 billion and net profit up 9.7% YoY to RMB 335 million. A medium price impact from the 15.5% revenue growth is estimated.
Ivonescimab is expected to receive Class I recommendations in the 2026 CSCO NSCLC guideline on April 28, 2026; a medium price impact (≥5%) is estimated as guideline inclusion significantly boosts commercial outlook expected
Announced the appointment of Dr. Kang Xiaoyan as Chief Medical Officer on April 28, 2026, to strengthen its R&D management team. Analysts estimate low importance as management changes typically result in a <5% price impact, estimated.
Conducted a share buyback of 3.65 million shares for HK$20.05 million on April 28, 2026. Analysts estimate low importance as the buyback size relative to market capitalization suggests a <5% price impact, estimated.
Received CE Mark approval for the Stealth AXiS surgical system for spine and cranial procedures in Europe on 2026-04-28.
WuXi AppTec announced its Q1 2026 financial results on 2026-04-27, reporting a 28.8% year-over-year increase in revenue to CNY 12.44 billion and a 71.7% increase in adjusted non-IFRS net profit to CNY 4.60 billion, leading to a significant stock price increase.
On April 27, 2026, Eli Lilly announced a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion to expand its hematology pipeline. High importance is assigned based on the strategic value of the acquisition and an estimated price impact of over 10%.
CSPC Innovation Pharmaceutical announced Q1 2026 results on 2026-04-27; revenue grew 40.8% but net loss widened 248.9% to RMB 93.9 million, which is estimated to cause a medium negative price impact of approximately 5-10%. expected
Announcement of unaudited Q1 2026 results on 2026-04-27: revenue increased 45.1% YoY and net loss narrowed by 91.2%; estimated price impact ≥5% due to significant profitability improvement expected.
Announced Q1 2026 results: revenue grew 16.9% YoY to RMB 1.8B, while net profit fell 6.8% to RMB 304M due to forex losses. Adjusted net profit rose 27.9%.
Announced that the U.S. FDA approved a supplemental New Drug Application (sNDA) for CAPLYTA® (lumateperone) to be used for the prevention of relapse in adults with schizophrenia.
Announced the U.S. FDA has granted Priority Review for the supplemental Biologics License Application (sBLA) for IMAAVY® (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA).
Presentation of positive clinical trial data for FARAPULSE and WATCHMAN devices at the Heart Rhythm 2026 conference on 2026-04-26. This event is estimated to have a 1-5% price impact, scheduled.
Alphabet announced an investment of up to $40 billion in AI startup Anthropic on April 25, 2026, deepening its partnership.
Announced positive clinical study milestones for its Affera cardiac arrhythmia technologies, including FDA Breakthrough Device designation for the Sphere-9 catheter on 2026-04-25.
Announced the completion of the main structure and arrival of key equipment for its new microbial commercial manufacturing site in Chengdu, with GMP production scheduled to begin by the end of 2026; Medium importance justified by capacity expansion likely causing ≥5% price impact.
Selective KAT6 inhibitor (SYH2095) received U.S. FDA clinical trial approval on 2026-04-24; this regulatory milestone is estimated to have a low positive price impact of approximately 1-5%. scheduled
Announced a RMB 2 billion investment to expand its chemical macromolecule CDMO R&D and production base in the Tianjin Economic-Technological Development Area.
Proposed spin-off and separate HKEX listing of Mandi Inc. with a conditional special dividend via distribution in specie of Mandi shares to qualifying 3SBio shareholders; shareholder approval was scheduled at an extraordinary general meeting on 2026-04-23.
Announced that three of its production facilities in Wuxi received Good Manufacturing Practice (GMP) certification from South Korea's Ministry of Food and Drug Safety (MFDS); Medium importance justified by expanded market access likely causing ≥5% price impact.